Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guilhem Roubaud

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
European Urology Oncology|July 19, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaGéraldine Pignot, Antoine Thiery-Vuillemin, Laurence Albigès, et al.
Cancers|September 10, 2021
Biomarker in Active Surveillance for Prostate Cancer: A Systematic ReviewCécile Manceau, Gaëlle Fromont, Jean-Baptiste Beauval, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
World Journal of Urology|January 3, 2025
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinomaGeraldine Pignot, Gaelle Margue, Pierre Bigot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Clinical Genitourinary Cancer|March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 StudyStéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
World Journal of Urology|November 7, 2022
Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimensAlberto Martini, Alae Touzani, Jean-Baptiste Beauval, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
European Urology Oncology|July 19, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaGéraldine Pignot, Antoine Thiery-Vuillemin, Laurence Albigès, et al.
Cancers|September 10, 2021
Biomarker in Active Surveillance for Prostate Cancer: A Systematic ReviewCécile Manceau, Gaëlle Fromont, Jean-Baptiste Beauval, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
World Journal of Urology|January 3, 2025
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinomaGeraldine Pignot, Gaelle Margue, Pierre Bigot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Clinical Genitourinary Cancer|March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 StudyStéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
World Journal of Urology|November 7, 2022
Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimensAlberto Martini, Alae Touzani, Jean-Baptiste Beauval, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
Pageof 10